177 related articles for article (PubMed ID: 33118048)
1. A global antiB cell strategy combining obinutuzumab and daratumumab in severe pediatric nephrotic syndrome.
Dossier C; Prim B; Moreau C; Kwon T; Maisin A; Nathanson S; De Gennes C; Barsotti K; Bourrassi A; Hogan J; Deschênes G
Pediatr Nephrol; 2021 May; 36(5):1175-1182. PubMed ID: 33118048
[TBL] [Abstract][Full Text] [Related]
2. Obinutuzumab in Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome in Children.
Dossier C; Bonneric S; Baudouin V; Kwon T; Prim B; Cambier A; Couderc A; Moreau C; Deschenes G; Hogan J
Clin J Am Soc Nephrol; 2023 Dec; 18(12):1555-1562. PubMed ID: 37678236
[TBL] [Abstract][Full Text] [Related]
3. Successful global anti-B-cell strategy with daratumumab in a patient with post-transplant nephrotic syndrome recurrence unresponsive to immunoadsorption and obinutuzumab.
Delbet JD; Hogan J; Parmentier C; Ulinski T; Dossier C
Pediatr Transplant; 2023 Aug; 27(5):e14544. PubMed ID: 37226549
[TBL] [Abstract][Full Text] [Related]
4. Age and memory B cells at baseline are associated with risk of relapse and memory B-cell reappearance following anti-CD20 treatment in pediatric frequently-relapsing/steroid-dependent nephrotic syndrome.
Colucci M; Angeletti A; Zotta F; Carsetti R; Lugani F; Ravà L; Ravani P; Emma F; Ghiggeri GM; Vivarelli M
Kidney Int; 2023 Sep; 104(3):577-586. PubMed ID: 37385541
[TBL] [Abstract][Full Text] [Related]
5. Ofatumumab in two pediatric nephrotic syndrome patients allergic to rituximab.
Vivarelli M; Colucci M; Bonanni A; Verzani M; Serafinelli J; Emma F; Ghiggeri G
Pediatr Nephrol; 2017 Jan; 32(1):181-184. PubMed ID: 27687621
[TBL] [Abstract][Full Text] [Related]
6. Human or Chimeric Monoclonal Anti-CD20 Antibodies for Children with Nephrotic Syndrome: A Superiority Randomized Trial.
Ravani P; Colucci M; Bruschi M; Vivarelli M; Cioni M; DiDonato A; Cravedi P; Lugani F; Antonini F; Prunotto M; Emma F; Angeletti A; Ghiggeri GM
J Am Soc Nephrol; 2021 Oct; 32(10):2652-2663. PubMed ID: 34544820
[TBL] [Abstract][Full Text] [Related]
7. Relapse of nephrotic syndrome during post-rituximab peripheral blood B-lymphocyte depletion.
Sato M; Kamei K; Ogura M; Ishikura K; Ito S
Clin Exp Nephrol; 2018 Feb; 22(1):110-116. PubMed ID: 28434126
[TBL] [Abstract][Full Text] [Related]
8. Idiopathic nephrotic syndrome and rituximab: may we predict circulating B lymphocytes recovery?
Delbet JD; Leclerc G; Ulinski T
Pediatr Nephrol; 2019 Mar; 34(3):529-532. PubMed ID: 30542932
[TBL] [Abstract][Full Text] [Related]
9. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07).
Horinouchi T; Sako M; Nakanishi K; Ishikura K; Ito S; Nakamura H; Oba MS; Nozu K; Iijima K
BMC Nephrol; 2018 Nov; 19(1):302. PubMed ID: 30382824
[TBL] [Abstract][Full Text] [Related]
10. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.
Morschhauser F; Le Gouill S; Feugier P; Bailly S; Nicolas-Virelizier E; Bijou F; Salles GA; Tilly H; Fruchart C; Van Eygen K; Snauwaert S; Bonnet C; Haioun C; Thieblemont C; Bouabdallah R; Wu KL; Canioni D; Meignin V; Cartron G; Houot R
Lancet Haematol; 2019 Aug; 6(8):e429-e437. PubMed ID: 31296423
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for relapse and long-term outcome in steroid-dependent nephrotic syndrome treated with rituximab.
Kamei K; Ogura M; Sato M; Sako M; Iijima K; Ito S
Pediatr Nephrol; 2016 Jan; 31(1):89-95. PubMed ID: 26341251
[TBL] [Abstract][Full Text] [Related]
12. Anti-rituximab antibodies in pediatric steroid-dependent nephrotic syndrome.
Bertrand Q; Mignot S; Kwon T; Couderc A; Maisin A; Cambier A; Baudouin V; Peyneau M; Deschênes G; Hogan J; Dossier C
Pediatr Nephrol; 2022 Feb; 37(2):357-365. PubMed ID: 34132894
[TBL] [Abstract][Full Text] [Related]
13. Effect of different rituximab regimens on B cell depletion and time to relapse in children with steroid-dependent nephrotic syndrome.
Hogan J; Dossier C; Kwon T; Macher MA; Maisin A; Couderc A; Niel O; Baudouin V; Deschênes G
Pediatr Nephrol; 2019 Feb; 34(2):253-259. PubMed ID: 30109447
[TBL] [Abstract][Full Text] [Related]
14. Rituximab modulates T- and B-lymphocyte subsets and urinary CD80 excretion in patients with steroid-dependent nephrotic syndrome.
Bhatia D; Sinha A; Hari P; Sopory S; Saini S; Puraswani M; Saini H; Mitra DK; Bagga A
Pediatr Res; 2018 Oct; 84(4):520-526. PubMed ID: 29983411
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Efficacy and Safety of Repeated Rituximab to Maintain Remission in Idiopathic Childhood Nephrotic Syndrome: An International Study.
Chan EY; Yu ELM; Angeletti A; Arslan Z; Basu B; Boyer O; Chan CY; Colucci M; Dorval G; Dossier C; Drovandi S; Ghiggeri GM; Gipson DS; Hamada R; Hogan J; Ishikura K; Kamei K; Kemper MJ; Ma AL; Parekh RS; Radhakrishnan S; Saini P; Shen Q; Sinha R; Subun C; Teo S; Vivarelli M; Webb H; Xu H; Yap HK; Tullus K
J Am Soc Nephrol; 2022 Jun; 33(6):1193-1207. PubMed ID: 35354600
[TBL] [Abstract][Full Text] [Related]
16. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial.
Iijima K; Sako M; Nozu K; Mori R; Tuchida N; Kamei K; Miura K; Aya K; Nakanishi K; Ohtomo Y; Takahashi S; Tanaka R; Kaito H; Nakamura H; Ishikura K; Ito S; Ohashi Y;
Lancet; 2014 Oct; 384(9950):1273-81. PubMed ID: 24965823
[TBL] [Abstract][Full Text] [Related]
17. Rituximab for very low dose steroid-dependent nephrotic syndrome in children: a randomized controlled study.
Ravani P; Lugani F; Pisani I; Bodria M; Piaggio G; Bartolomeo D; Prunotto M; Ghiggeri GM
Pediatr Nephrol; 2020 Aug; 35(8):1437-1444. PubMed ID: 32232637
[TBL] [Abstract][Full Text] [Related]
18. Rituximab treatment in pediatric patients with steroid-dependent nephrotic syndrome: A tertiary hospital.
Guzmán Morais B; Ordóñez Álvarez FÁ; Santos Rodríguez F; Martín Ramos S; Fernández Novo G
An Pediatr (Engl Ed); 2022 Feb; 96(2):83-90. PubMed ID: 35144901
[TBL] [Abstract][Full Text] [Related]
19. Rituximab efficiency in children with steroid-dependent nephrotic syndrome.
Sellier-Leclerc AL; Macher MA; Loirat C; Guérin V; Watier H; Peuchmaur M; Baudouin V; Deschênes G
Pediatr Nephrol; 2010 Jun; 25(6):1109-15. PubMed ID: 20238230
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of long-term repeated use of rituximab in pediatric patients with nephrotic syndrome.
Choi N; Min J; Kim JH; Kang HG; Ahn YH
Pediatr Nephrol; 2024 Mar; 39(3):771-780. PubMed ID: 37682369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]